- Home
- WGSWW vs ICUI Comparison
WGSWW vs ICUI Comparison
Compare WGSWW & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGSWW
- ICUI
- Stock Information
- Founded
- WGSWW N/A
- ICUI 1984
- Country
- WGSWW United States
- ICUI United States
- Employees
- WGSWW 1000
- ICUI N/A
- Industry
- WGSWW Retail: Computer Software & Peripheral Equipment
- ICUI Medical/Dental Instruments
- Sector
- WGSWW Technology
- ICUI Health Care
- Exchange
- WGSWW Nasdaq
- ICUI Nasdaq
- Market Cap
- WGSWW N/A
- ICUI N/A
- IPO Year
- WGSWW 2020
- ICUI 1992
- Fundamental
- Price
- WGSWW $0.14
- ICUI $155.34
- Analyst Decision
- WGSWW
- ICUI Strong Buy
- Analyst Count
- WGSWW 0
- ICUI 5
- Target Price
- WGSWW N/A
- ICUI $177.25
- AVG Volume (30 Days)
- WGSWW N/A
- ICUI 202.9K
- Earning Date
- WGSWW N/A
- ICUI 11-12-2024
- Dividend Yield
- WGSWW N/A
- ICUI N/A
- EPS Growth
- WGSWW N/A
- ICUI N/A
- EPS
- WGSWW N/A
- ICUI N/A
- Revenue
- WGSWW N/A
- ICUI $2,340,097,000.00
- Revenue This Year
- WGSWW N/A
- ICUI $4.38
- Revenue Next Year
- WGSWW N/A
- ICUI $0.34
- P/E Ratio
- WGSWW N/A
- ICUI N/A
- Revenue Growth
- WGSWW N/A
- ICUI 4.04
- 52 Week Low
- WGSWW N/A
- ICUI $86.80
- 52 Week High
- WGSWW N/A
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- WGSWW N/A
- ICUI 40.66
- Support Level
- WGSWW N/A
- ICUI $155.79
- Resistance Level
- WGSWW N/A
- ICUI $168.31
- Average True Range (ATR)
- WGSWW 0.00
- ICUI 3.87
- MACD
- WGSWW 0.00
- ICUI 0.22
- Stochastic Oscillator
- WGSWW 0.00
- ICUI 26.35
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.